2010 Kerrin Rennie Award
Medical technology saves and improves lives by detecting diseases earlier and by providing more effective treatment options for patients and the healthcare system. The Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life recognises the innovative and extraordinary contribution of medical technology in improving health outcomes of Australian patients.
The award is a great opportunity for medical technology companies to showcase their innovative products.
This award is endowed by the family of the late Kerrin Rennie who was a long standing member of the Australian medical technology community.
Entries for the 2011 Kerrin Rennie Award will open in May. Please register your interest by emailing reception@mtaa.org.au
The winner of the 2010 Kerrin Rennie Award is:
SynCardia – Device Technologies
SynCardia is a temporary total artificial heart enabling patients with end-stage heart disease to survive until a replacement heart becomes available. The device temporarily replaces both failing heart ventricles and heart valves. Its high volume blood flow helps patients recover to become better transplant candidates.
The other finalists were:
Nucleus 5 System – Cochlear
The Nucleus 5 system consists of four components: Cochlear implant, sound processor, remote assistant and software. It restores hearing to individuals with severe to profound hearing loss. The Nucleus 5 includes the world’s thinnest implant and dual omni directional microphones simplifying phone use. It has increased impact, water and sweat resistance.
SureScan Pacing System – Medtronic
The SureScan Pacing system is an MRI compatible pacemaker. It is designed to overcome complications associated with MRI scans allowing previously restricted pacemaker patients to undergo less invasive and more effective diagnosis.
Synvisc One - Genzyme
Synvisc One is a gel like fluid that treats the cause of pain and decrease in join mobility associated with osteoarthritis. The gel simulates healthy synovial fluid in affected joints. Synvisc One requires fewer injections lasting up to six months.
Follow this link to view past Kerrin Rennie Award finalists and winners from 2007-2009.
